ProCE Banner Activity

CITADEL-204 Phase II Trial of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed/Refractory Marginal Zone Lymphoma

Slideset Download
Conference Coverage
Parsaclisib active in BTK inhibitor–naive patients with R/R MZL across nodal, extranodal, or splenic subtypes.

Released: December 08, 2020

Expiration: December 07, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology